21
Participants
Start Date
July 13, 2018
Primary Completion Date
October 8, 2019
Study Completion Date
October 8, 2019
Betrixaban
Factor Xa inhibitor.
Children's Healthcare of Atlanta, Atlanta
Rainbow Babies & Children's Hospital, Cleveland
Tulane Medical Center, New Orleans
Ivano-Frankivsk Regional Children Clinical Hospital, Ivano-Frankivsk
Children's Hospital Los Angeles, Los Angeles
ACTCA, Axis Clinical Trials, Los Angeles
Children's City Clinical Hospital, Moscow
Pirogov Russian National Research Medical University, Moscow
Saint Petersburg State Pediatric Medical University, Saint Petersburg
Children's Hospital of Tatarstan Republic, Kazan'
State Budgetary Institution, Nizhny Novgorod
Federal State Institution, Kemerovo
Odessa Regional Children Clinical Hospital, Odesa
Sumy Regional Children's Hospital, Sumy
Vinnytsia Regional Children's Clinical Hospital, Department of Anesthesiology and Intensive Care, Vinnitsa
Birmingham Women's and Children's NHS Foundation Trust, Birmingham
Addenbrooke's Hospital, Cambridge
Children's Hospital for Wales, Cardiff
Glenfield Hospital, Leicester
Evelina London Children's Hospital, London
Lead Sponsor
Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)
INDUSTRY
Alexion Pharmaceuticals, Inc.
INDUSTRY